Kings Point Capital Management’s Biogen BIIB Stock Holding History

Kings Point Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-510	Closed	-$143K	–	545
2021 Q1	$143K	Sell	510 -200	-28%	-$53.9K	0.01%	229
2020 Q4	$174K	Hold	710	–	–	0.02%	198
2020 Q3	$201K	Buy	710 +510	+255%	+$142K	0.03%	176
2020 Q2	$54K	Hold	200	–	–	0.01%	271
2020 Q1	$63K	Buy	+200	New	+$60.7K	0.01%	252
2017 Q4	–	Sell	-150	Closed	-$47K	–	373
2017 Q3	$47K	Buy	+150	New	+$44.4K	0.01%	227
2016 Q3	–	Sell	-600	Closed	-$145K	–	307
2016 Q2	$145K	Buy	+600	New	+$158K	0.04%	133
2015 Q3	–	Sell	-59	Closed	-$24K	–	369
2015 Q2	$24K	Hold	59	–	–	0.01%	287
2015 Q1	$25K	Sell	59 -140	-70%	-$55.2K	0.01%	282
2014 Q4	$68K	Buy	199 +140	+237%	+$45.3K	0.02%	176
2014 Q3	$20K	Buy	+59	New	+$19.5K	0.01%	250

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Kings Point Capital Management's BIIB Position: Q2 2021 in Review

Kings Point Capital Management sold out of Biogen (BIIB) in Q2 2021, closing a stake of 510 shares — an estimated $143K sold.

Kings Point Capital Management first reported a position in BIIB in Q3 2014 and held it in 11 quarters. The position peaked at $201K in Q3 2020. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Kings Point Capital Management reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Kings Point Capital Management sold 510 Biogen shares in Q2 2021, an estimated $143K.
Kings Point Capital Management first reported a position in Biogen in Q3 2014 and held it in 11 quarters.
Kings Point Capital Management's Biogen position peaked at $201K in Q3 2020.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Kings Point Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.